Stefan Schreiber

Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Impact of Moderate to Severe Crohn’s Disease Symptoms on Health Care Professional Treatment Decisions in the United States and Europe

1 Icahn School of Medicine at Mount Sinai, New York, New York, United States; 2 Eli Lilly and Company, Indianapolis, Indiana, United States; 3 University of Oxford, Oxford, United Kingdom...

Alison Potts Bleakman ;

Cem Kayhan ;

Christian Atkinson ;

Marla C. Dubinsky , MD;

Toshifumi Hibi ;

Theresa Hunter Gibble ;

Simon Travis ;

Tommaso Panni ;

Remo Panaccione ;

Angelo D. Favia ;

Stefan Schreiber ;

David T. Rubin , MD;

01/11/2024

Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: United States and European Patient Perspectives on the Impact of Moderate to Severe Crohn’s Disease on Sexual Activity

1 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, United States; 2 Eli Lilly and Company, Indianapolis, Indiana, United States; 3 University of Oxford...

Remo Panaccione ;

Stefan Schreiber ;

Alison Potts Bleakman ;

Cem Kayhan ;

Christian Atkinson ;

Toshifumi Hibi ;

Marla C. Dubinsky , MD;

Simon Travis ;

David T. Rubin , MD;

Tommaso Panni ;

Angelo D. Favia ;

Theresa Hunter Gibble ;

01/11/2024

Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial

1 Nancy University Hospital, Vandoeuvre-les-Nancy, France; 2 GI Alliance, United States; 3 Icahn School of Medicine at Mount Sinai, New York, United States; 4 UNIMI, Department of Pathoph...

Xiu Huang ;

Sofie Berg ;

Lei Shu ;

Kristina Kligys ;

Remo Panaccione ;

Marc Ferrante ;

Britta Siegmund ;

Jean-Frederic Colombel ;

Ezequiel Neimark ;

Geert D'Haens ;

Kori Wallace ;

Marla C. Dubinsky , MD;

Peter Irving ;

W. Rachel Duan ;

Flavio Caprioli ;

Stefan Schreiber ;

Laurent Peyrin-Biroulet ;

Raja Atreya ;

Silvio Danese ;

James O. Lindsay ;

Casey Chapman ;

Peter Bossuyt ;

Toni Anschutz ;

Valerie Pivorunas ;

01/11/2024

Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

1 University Hospital CHU of Liège, Liège, Belgium, Liège, Belgium; 2 University of Calgary, Calgary, Alberta, Canada; 3 Barts Health NHS Trust, London, United Kingdom; 4 NGERE, Faculty o...

Su Chen ;

W. Rachel Duan ;

Alessandro Armuzzi ;

Luc Biedermann ;

Stefan Schreiber ;

Edouard Louis ;

Remo Panaccione ;

Gareth Parkes ;

Laurent Pevrin-Biroulet ;

Marc Ferrante ;

Britta Siegmund ;

Phillip Levine ;

Gil Y. Melmed , MD;

Jasmina Kalabic ;

Ken Takeuchi , MD, PhD;

Ezequiel Neimark ;

Edward V. Loftus Jr., MD;

Kori Wallace ;

01/11/2024

BACKGROUND: BI 695501 has demonstrated bioequivalence to both the US-licensed and EU-approved adalimumab reference product (RP) in rheumatoid arthritis. The aim of this head-to-head trial...

Stephen B. Hanauer , MD;

Sigrid Balser ;

Bernd Liedert ;

Stefan Schreiber ;

12/13/2019